Pair page
Pancragen with Semaglutide
Mechanism-tag overlap and published literature for Pancragen and Semaglutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
khavinson-pancreatic-bioregulator
glp-1-receptor-agonistmetabolic
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Pancragen and Semaglutide have published these mechanism-level observations. Not a co-administration recommendation.
GLP-1 receptor agonists stimulate insulin secretion, slow gastric emptying, and reduce appetite. Pancragen's proposed β-cell protective effects could complement GLP-1 therapy by preserving the insulin-producing capacity that GLP-1 agonists rely on. Pancragen is not a substitute for semaglutide — semaglutide is FDA-approved with rigorous Phase 3 evidence.
Quick facts
Pancragen
Semaglutide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2021 | Pancragen | Khavinson V, Popovich I, Linkova N, Mironova E, Ilina A. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834146. PMID 34834146 | systematic review |
| 2020 | Pancragen | Khavinson VKh, Kuznik BI, Trofimova SV, Lin'kova NS. Cortexin and its short peptides AEDG and EDR modulate gene expression of proteins in pathogenesis of Alzheimer's disease. Biomed Khim. 2020. (Parallel framework evidence for the Khavinson short-peptide gene-expression paradigm… | mechanism / discovery |
| 2020 | Pancragen | Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis. Int J Mol Sci. 2020;21(2):609. PMID: 31963526. PMID 31963526 | mechanism / discovery |
| 2015 | Pancragen | Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic Mechanisms of Peptidergic Regulation of Gene Expression during Aging of Human Cells. Biochemistry (Mosc). 2015;80(3):310-322. PMID: 25761684. PMID 25761684 | mechanism / discovery |
| 2020 | Pancragen | Khavinson VK. Peptide regulation of ageing: 40 years of research. Adv Gerontol. 2020. (Retrospective review of the Khavinson peptide program; Pancragen placed in context.) | review |
| 2022 | Pancragen | Khavinson VK, Kuznik BI, Lin'kova NS, et al. Peptide Medicines: Past, Present, Future. Clin Med (Russian Journal). 2022;100(1):5-13. (Comprehensive framework review placing Pancragen in broader bioregulator context.) | bioregulator literature |
| 2022 | Pancragen | Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of aging: methodology and evidence. Bull Exp Biol Med. 2022. | bioregulator literature |
| 2020 | Pancragen | Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation, Proliferation, and Apoptosis. Adv Gerontol. 2020;10(2):98-106. | bioregulator literature |
| 2019 | Pancragen | Kolchina N, Khavinson V, Linkova N, Yakutseni P, Petukhov M, Morozova E, Ashapkin V. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Res. 2019;47(20):10553-10563. PMID: 31584079. PMID 31584079 | bioregulator literature |
| 2015 | Pancragen | Linkova NS, Drobintseva AO, Orlova OA, et al. Peptide regulation of beta-cell function during aging. Adv Gerontol. 2015;28(3):478-484. | bioregulator literature |
| 2010 | Pancragen | Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19633997. PMID 19633997 | bioregulator literature |
| 2005 | Pancragen | Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger; Basel; 2005. (Monograph; framework reference for all Khavinson peptides including Pancragen.) | bioregulator literature |
| 2024 | Semaglutide | Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. PMID: 38785209. PMID 38785209 | human trial |
| 2023 | Semaglutide | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. PMID 37952131 | human trial |
| 2022 | Semaglutide | Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID: 36216945. PMID 36216945 | human trial |
| 2022 | Semaglutide | Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037. PMID 35015037 | human trial |
| 2021 | Semaglutide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. PMID 33567185 | human trial |
| 2021 | Semaglutide | Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417. PMID 33667417 | human trial |
| 2021 | Semaglutide | Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. PMID: 33625476. PMID 33625476 | human trial |
| 2021 | Semaglutide | Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728. PMID 33755728 | human trial |
| 2021 | Semaglutide | Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364. PMID 33185364 | human trial |
| 2019 | Semaglutide | Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. PMID: 31186300. PMID 31186300 | human trial |
| 2016 | Semaglutide | Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186. PMID 27633186 | human trial |
| 2019 | Semaglutide | Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. PMID: 31031702. PMID 31031702 | mechanism / discovery |
Related pair pages
More research context
Frequently asked
Have Pancragen and Semaglutide been studied together?
Researchers have published mechanistic-level co-administration discussion of Pancragen and Semaglutide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Pancragen and Semaglutide share?
Pancragen and Semaglutide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Pancragen and Semaglutide?
Pancragen: Not approved. Semaglutide: Approved (2017). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Pancragen and Semaglutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Pancragen profile and the Semaglutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026